Chicago Equity Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Chicago Equity Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$333K	Buy	+1,157	New	+$319K	0.03%	514

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Chicago Equity Partners's KPTI Position: Q1 2020 in Review

Chicago Equity Partners opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2020: 1,157 shares worth $333K. The stake represents 0.03% of the portfolio and ranks #514 among its holdings.

136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Chicago Equity Partners held 1,157 shares of Karyopharm Therapeutics worth $333K as of Q1 2020.
Karyopharm Therapeutics was a new Chicago Equity Partners position in Q1 2020.
Karyopharm Therapeutics made up 0.03% of Chicago Equity Partners's portfolio in Q1 2020, its #514 holding.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.